Genetic regulation and targeted reversal of lysosomal dysfunction and inflammatory sterol metabolism in pulmonary arterial hypertension
Lloyd D. Harvey,Mona Alotaibi,Hee-Jung J. Kim,Yi-Yin Tai,Ying Tang,Wei Sun,Wadih El Khoury,Chen-Shan C. Woodcock,Yassmin Al Aaraj,Claudette M. St. Croix,Donna B. Stolz,Ji Young Lee,Mary Hongying Cheng,Tae-Hwi Schwantes-An,Ankit A. Desai,Michael W. Pauciulo,William C. Nichols,Amy Webb,Robert Lafyatis,Mehdi Nouraie,Haodi Wu,Jeffrey G. McDonald,Caroline Chauvet,Susan Cheng,Ivet Bahar,Thomas Bertero,Raymond L. Benza,Mohit Jain,Stephen Y. Chan
DOI: https://doi.org/10.1101/2024.02.26.582142
2024-03-01
Abstract:Vascular inflammation critically regulates endothelial cell (EC) pathophenotypes, particularly in pulmonary arterial hypertension (PAH). Dysregulation of lysosomal activity and cholesterol metabolism have known inflammatory roles in disease, but their relevance to PAH is unclear. In human pulmonary arterial ECs and in PAH, we found that inflammatory cytokine induction of the nuclear receptor coactivator 7 ( ) both preserved lysosomal acidification and served as a homeostatic brake to constrain EC immunoactivation. Conversely, NCOA7 deficiency promoted lysosomal dysfunction and proinflammatory oxysterol/bile acid generation that, in turn, contributed to EC pathophenotypes. , mice deficient for or exposed to the inflammatory bile acid 7α-hydroxy-3-oxo-4-cholestenoic acid (7HOCA) displayed worsened PAH. Emphasizing this mechanism in human PAH, an unbiased, metabolome-wide association study (N=2,756) identified a plasma signature of the same NCOA7-dependent oxysterols/bile acids associated with PAH mortality ( <1.1x10 ). Supporting a genetic predisposition to NCOA7 deficiency, in genome-edited, stem cell-derived ECs, the common variant intronic SNP rs11154337 in regulated NCOA7 expression, lysosomal activity, oxysterol/bile acid production, and EC immunoactivation. Correspondingly, SNP rs11154337 was associated with PAH severity via six-minute walk distance and mortality in discovery (N=93, =0.0250; HR=0.44, 95% CI [0.21-0.90]) and validation (N=630, =2x10 ; HR=0.49, 95% CI [0.34-0.71]) cohorts. Finally, utilizing computational modeling of small molecule binding to NCOA7, we predicted and synthesized a novel activator of NCOA7 that prevented EC immunoactivation and reversed indices of rodent PAH. In summary, we have established a genetic and metabolic paradigm and a novel therapeutic agent that links lysosomal biology as well as oxysterol and bile acid processes to EC inflammation and PAH pathobiology. This paradigm carries broad implications for diagnostic and therapeutic development in PAH and in other conditions dependent upon acquired and innate immune regulation of vascular disease.
Physiology